Vimizim (Elosulfase alfa Vials) 1mg/ml x 5ml

Vimizim (elosulfase alfa) is an enzyme replacement therapy for mucopolysaccharidosis type IVA (Morquio A syndrome). This 1mg/ml x 5ml vial formulation supports lysosomal storage disorder management. Store between 2-8°C and protect from light. Prescription required.

Strength

1mg/ml x 5ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Biomarin

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vimizim is used for enzyme replacement therapy in patients with confirmed mucopolysaccharidosis type IVA (Morquio A syndrome). It helps address the underlying enzyme deficiency that causes glycosaminoglycan buildup. This medication is designed to improve mobility and respiratory function in eligible patients. Common questions include what is Vimizim used for and how it supports metabolic health.

Side Effects

Vimizim works by replacing the deficient enzyme that breaks down glycosaminoglycans in the body. Patients may notice improved endurance and reduced fatigue over time with consistent use. Some individuals report better joint mobility and breathing comfort during daily activities. Effects vary based on individual response and treatment duration.

Precautions & Warnings

Vimizim requires careful handling and storage at 2-8°C to maintain potency. Always check the vial for particles or discoloration before use. Patients should follow healthcare provider instructions for administration timing and monitoring. Avoid exposure to extreme temperatures or direct sunlight during transport.

Avoid Interactions

Limited data exists on drug interactions with Vimizim. Patients should inform healthcare providers about all medications, including over-the-counter products. No specific interactions are widely reported, but caution is advised with other intravenous therapies. Alcohol consumption should be discussed with a medical professional.

References

Frequently Asked Questions

Vimizim is used as enzyme replacement therapy for mucopolysaccharidosis type IVA (Morquio A syndrome).

Vimizim is given as an intravenous infusion by healthcare professionals in a clinical setting.

Common effects may include headache, nausea, or infusion-related reactions like fever or chills.

No, Vimizim must be stored between 2-8°C and protected from light.

No, Vimizim requires a prescription from a licensed healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.